Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-07-21
2008-11-18
Tsang, Cecilia J (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S183000, C514S009100
Reexamination Certificate
active
07452861
ABSTRACT:
This invention is directed to methods of administering an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms. The invention is also directed to methods of using an echinocandin antifungal agent in combination with a specified glycopeptide antibacterial agent to treat fungal infections; and to compositions, kits and systems comprising an echinocandin antifungal agent and a specified glycopeptide antibacterial agent.
REFERENCES:
patent: 5378804 (1995-01-01), Balkovec et al.
patent: 5925616 (1999-07-01), Whittemore
patent: 6107458 (2000-08-01), Ohki et al.
patent: 6267979 (2001-07-01), Raad et al.
patent: 6635618 (2003-10-01), Leadbetter et al.
patent: 6719991 (2004-04-01), Darouiche et al.
patent: 6743777 (2004-06-01), Burkhardt et al.
patent: 2003/0017975 (2003-01-01), Ikeda et al.
patent: 2004/0242505 (2004-12-01), Kaniga
patent: 2005/0026819 (2005-02-01), Kaniga
patent: 0 525 499 (1993-02-01), None
patent: 0 667 353 (1995-08-01), None
patent: WO 00/72865 (2000-12-01), None
Ge et al. Vancomycin Derivatives That Inhibit Peptidoglycan Biosynthesis Without Binding D-Ala-D-Ala. Sciene. Apr. 16, 1999. vol. 284, pp. 507-511.
Giglione et al. The situation on antimicrobial agents and chemotherapy in 2002: Highlights of the 42nd ICAAC. Sep. 27-30, 2002, San Diego, USA.Expert Opin. Ther. Targets. 2002. vol. 6 No. 6, pp. 691-697.
Boger. Vancomycin, Teicoplanin and Ramoplanin. Medicinal Research Reviews. 2001. vol. 21, No. 5, pp. 356-381.
Arikan et al., “New agents for the treatment of systemic fungal infections-current status”, Expert Opin. Emerging Drugs, 7(1), pp. 3-32 (2002).
Chiou et al., “Synergy, Pharmacodynamics, and Time-Sequenced Ultrastructural Changes of the Interaction between Nikkomycin Z and the Echinocandin FK463 againstAspergillus fumigatus”, Antimicrobial Agents and Chemotherapy, vol. 45, No. 12, pp. 3310-3321 (2001).
Denning, “Echinocandins:a new class of antifungal”, Journal of Antimicrobial Chemotherapy, 49, pp. 889-891 (2002).
Denning, “Echinocandin antifungal drugs”, The Lancet, vol. 362, pp. 1142-1151 (2003).
Eliopoulos et al., “Antimicrobial Combinations”, Antibiotics in Laboratory Medicine, 4th Edition, Williams & Wilkins, pp. 330-396 (1996).
Groll et al., “Caspofungin:pharmacology, safety and therapeutic potential in superficial and invasive fungal infections”, Expert Opin. Investig. Drugs, 10(8), pp. 1545-1558 (2001).
Hossain et al., “New investigational antifungal agents for treating invasive fungal infections”, Expert Opin. Invest. Drugs, 9(8), pp. 1797-1813 (2000).
Lewis et al., “Rationale for Combination Antifungal Therapy”, Pharmacotherapy, vol. 21, No. 8, pp. 149s-164s (2001).
Manavathu et al., “Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin againstAspergillus fumigatus”, J. of Antimicrobial Chemotherapy, 51, pp. 1423-1425 (2003).
Nicolaou et al., “Chemistry, Biology, and Medicine of the Glycopeptide Antibiotics”, Angew. Chem. Int. Ed., 38, pp. 2096-2152 (1999).
Shalit et al., “In Vitro Synergy of Caspofungin and Itraconazole againstAspergillusspp.: MIC versus Minimal Effective Concentration End Points”, Antimicrobial Agents and Chemotherapy, vol. 47, No. 4, pp. 1416-1418 (2003).
Sugar, “Overview: Antifungal combination therapy”, Current Opinion in Investigational Drugs, 2(10), pp. 1364-1365 (2001).
Vanden Bossche, “Echinocandins-an update”, Expert Opin. Ther. Patents, 12(2), pp. 151-167 (2002).
Lacroix, C., et al., “Echinocandins: a new class of antifungal agents”,Medicine et maladies infectieuses,33(4):183-191, Apr. 2003. (in French with English abstract).
Link, H., “Antimicrobial prophylaxis and therapy in neutropenia”,Mycoses46(Suppl. 2):21-32, Feb. 2003. (in German with English abstract).
Preobrazhenskaya, M. and Olsufyeva, E., “Patents on glycopeptides of the vancomycin family and their derivatives as antimicrobials: Jan. 1999-Jun. 2003”,Expert Opin. Ther. Patents,14(2):141-173, 2004.
Taccone F.S., et al., Caspofungin salvage therapy in a neutropenic patient with probable invasive aspergillosis: a case report,Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer,11(11):742-744, Nov. 2003.
Kureishi et al., “Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: Effect on cyclosporine A-associated nephrotoxicity”,Antimicrobial Agents and Chemotherapy,vol. 35 No. 11, pp. 2246-2252 (Nov. 1991).
Pace, John L., “TD-6424: A novel multifunctional antibiotic”,Abstr Intersci Conf Antimicrob Agents Chemother,42: Abstract No. 614, Sep. 27-30, 2002.
Office Action in U.S. Appl. No. 10/854,575, dated Nov. 24, 2006.
Office Action in U.S. Appl. No. 10/854,575, dated Apr. 27, 2007.
Office Action in U.S. Appl. No. 10/854,575, dated Aug. 6, 2007.
Cordero Garcia Marcela M
Hagenah Jeffrey A.
Theravance Inc.
Tsang Cecilia J
LandOfFree
Use of an echinocandin antifungal agent in combination with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of an echinocandin antifungal agent in combination with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of an echinocandin antifungal agent in combination with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4029966